Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More
Xconomy
JUNE 17, 2016
. —All the while, Merck (NYSE: MRK ) disclosed pembrolizumab (Keytruda) bested chemotherapy in a Phase 3 trial of previously untreated patients with non-small cell lung cancer; the study was stopped early because of the positive results. —Ben Fidler contributed to this report. Reprints | Share:
Let's personalize your content